ORTEXORTEX News
Tracking CGNX? Get live short interest, options flow, and signals on ORTEX.Sign up free →
CG
Trader NoteCGNX

Cognex Rallies 11% as Shorts Retreat and Street Watches Q3 Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 7 Oct 2026, 18:16

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

CGNX enters its November 6 earnings window on a strong footing, having gained 11% in a week to $66.35 while short sellers quietly reduce positions, yet with the Street growing more cautious on near-term targets.

The shift in short positioning is the most concrete data point of the week. Short interest has dropped 9% over the past month to 4.2% of the free float, unwinding a cluster that built through August and into early September when shares were lodged around 7.8 million short. The week-on-week reading nudged up fractionally, by 1.6%, but that follows a steady grind lower from a peak above 8.2 million shares in late August. Borrow conditions give no cause for concern: the cost to borrow is a negligible 0.37%, and availability is exceptionally loose at 1,375%, meaning the lending pool is barely tapped. That is well above the 52-week low availability of 385%, confirming this is not a stock under pressure from the short side. Options sentiment is correspondingly calm. The put/call ratio is 0.46, a touch above its 20-day average of 0.43 but only one standard deviation clear of it, nowhere near the defensive posturing the 52-week high of 0.60 would represent. Positioning, in aggregate, looks comfortable rather than charged.

The Street picture is more complicated. Truist Securities cut its price target to $74 from $78 on Monday, the most recent move, while maintaining a Hold rating. Baird similarly lowered its target to $70 from $78 in late September, and it too stayed Neutral. These trims follow what was a broadly constructive reaction to the August earnings print: Barclays lifted its target to $80, Needham held its Buy at $80, and Citigroup nudged up to $74. The mean target now sits at $79, implying roughly 19% upside to the current price of $66.35. HSBC's downgrade from Buy to Hold in August added some drag to sentiment, but the consensus still leans constructive, with bulls pointing to a pending $500 million RealSense acquisition that should expand exposure to robotic perception and physical AI, alongside guided Q3 EBITDA margins of 32% to 35% and estimated FY26 adjusted EPS of $1.68. Bears counter that 62% of sales run through short-cycle end markets including logistics, automotive, and consumer electronics, leaving results exposed to abrupt capex swings and customer concentration, with their scenario pointing to a 4% two-year revenue decline and EBITDA margins around 25%. Valuation sits at roughly 34 times trailing earnings and 27 times EV/EBITDA, with both multiples drifting modestly higher on the week as the stock rallied. The EV/EBIT factor score ranks in the 24th percentile, confirming that by this measure the stock is not cheap on a relative basis.

Retail attention has spiked. Wikipedia views are running at a z-score of 2.7 against the prior 90 days, the highest attention reading in the dataset. That is a colour point, not a financial signal, but it aligns with the strong price action and suggests a broader audience has taken notice of the year-to-date rally, which recent notes place at over 60%.

The insider register for August tells a more neutral story. CEO Matthew Moschner exercised options and sold into strength on August 11, with net open-market sales totalling roughly $1.6 million across several tranches at prices between $63.60 and $65.36. The transactions were not flagged under a 10b5-1 plan, but exercise-and-sell activity from a relatively new CEO following a significant run-up is not uncommon. The 90-day net position across all insiders is negative 45,214 shares at a net value of approximately $2.9 million sold, a modest figure against the company's size and not out of step with post-rally option monetisation. Institutional holders look stable. BlackRock leads with 9.5% of shares, last reported as of September 30 with a modest addition of 297,000 shares. Invesco added more meaningfully, bringing in close to 4 million shares to reach 4.1% of the register. T. Rowe Price added 1.5 million shares. No 13D activists are on the register; the only 5%-plus passive filings are from Vanguard entities.

Earnings reactions in recent history carry a consistent pattern worth noting. The August print produced a 5.4% one-day decline and a 12.9% five-day decline, while a prior event saw a 5.8% one-day drop and a 15.2% five-day pullback. With the next print 30 days away, the key tension is whether the recovering short-cycle demand narrative and RealSense integration story can hold the recent gains against a stock that has repeatedly sold off sharply on results day regardless of guidance direction.

Stocks in this article

See the live data behind this article on ORTEX.

Open CGNX on ORTEX →

How this article was generated

Generated
7 Oct 2026, 18:20
Data as of
7 Oct 2026, 18:16
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.